title: Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy.
abstract: HIV-infected patients receiving highly active antiretroviral therapy (HAART) are at increased risk of cardiovascular events. Reported non-invasive techniques for assessment of blood pressure in this population have been limited to sphygmomanometry. The present crosssectional study investigated the impact of antiretroviral therapy and the HAART-associated lipodystrophy on aortic blood pressure conditions and arterial stiffness in HAART-treated lipodystrophic (n=42) and non-lipodystrophic (n=17) patients. Pulse wave analysis, novel to this population, was used to evaluate measures of arterial stiffness, including the heart rate corrected augmentation index, AgI(HR). Results indicated no significant difference between the study groups in peripheral or aortic blood pressure and AgI(HR). Significant correlates of AgI(HR) included age (P = 0.003), duration of antiretroviral therapy (P = 0.020), lamivudine therapy (P = 0.015) and ritonavir therapy (P = 0.016) as well as cumulative exposure to protease inhibitors (P = 0.030). Time since HIV diagnosis, severity of immunodeficiency or presence of HAART-associated lipodystrophy bore no relationship to AgI(HR). In multivariate analysis, duration of antiretroviral therapy (P = 0.046), cumulative exposure to nucleoside reverse transcriptase inhibitors (P = 0.032) and to protease inhibitors (P = 0.011) were identified as independent factors predicting AgI(HR). Prolonged antiretroviral treatment, thus, delineates as a risk factor for systemic arterial stiffness and the associated cardiovascular mortality.
authors.affiliation: Department of Medicine, Division of Diabetes, Helsinki University Central Hospital, Helsinki, Finland. ksenia.sevastianova@helsinki.fi
authors.forename: Ksenia
authors.initials: K
authors.lastname: Sevastianova
authors.forename: Jussi
authors.initials: J
authors.lastname: Sutinen
authors.forename: Jukka
authors.initials: J
authors.lastname: Westerbacka
authors.forename: Matti
authors.initials: M
authors.lastname: Ristola
authors.forename: Hannele
authors.initials: H
authors.lastname: Yki-Järvinen
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D001011:Aorta; D001018:Aortic Diseases / Q000139:chemically induced* / Q000503:physiopathology; D001158:Arteries; D001769:Blood; D001794:Blood Pressure; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006784:Hospitals, Teaching; D006801:Humans; D008297:Male; D016491:Peripheral Vascular Diseases / Q000139:chemically induced* / Q000503:physiopathology; D019722:Sphygmomanometers
chemical_list: D019380:Anti-HIV Agents